Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
June 20 2019 - 07:00AM
Business Wire
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a
biopharmaceutical company focused on novel and targeted oncology
therapies, announced today the appointment of Elizabeth Czerepak to
the Board of Directors. Ms. Czerepak will also serve as the chair
of Spectrum’s audit committee.
“Elizabeth has a strong track record of financial leadership in
various roles throughout her career including as a CFO, a venture
capitalist and leader of business development groups,” said Joe
Turgeon, President and CEO of Spectrum Pharmaceuticals. “We welcome
her expertise and look forward to her guidance as we grow and
advance our development pipeline.”
Czerepak has more than thirty-five years of financial leadership
and strategy development experience across the pharmaceutical and
biotechnology fields. Ms. Czerepak currently serves as the Chief
Financial Officer and Chief Business Officer of Genevant Sciences,
Inc. Prior experience includes CFO roles at other biotechnology
companies, including Altimmune, Inc., Isarna Therapeutics, and
Cancer Genetics. She also has extensive experience in biotech
venture capital investment as a Managing Director at JP Morgan/Bear
Stearns. Her roles have provided her expertise in corporate
M&A, business development, product launches and strategic
planning.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
drug products, with a primary focus in hematology and oncology.
Spectrum has a strong track record of successfully executing across
the biopharmaceutical business model, from in-licensing and
acquiring differentiated drugs, clinically developing novel assets,
successfully gaining regulatory approvals and commercializing in a
competitive healthcare marketplace. Spectrum has a late-stage
pipeline with novel assets that serve areas of unmet need. This
pipeline has the potential to transform the company in the near
future. More information on Spectrum is available at
www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® are registered trademarks of
Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING
CANCER CARE™ and the Spectrum Pharmaceuticals’ logos are trademarks
owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are
the property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190620005105/en/
COMPANY CONTACT Shiv Kapoor Vice President, Strategic
Planning & Investor Relations 702-835-6300
InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2023 to Mar 2024